

Form PTO-1594 (Rev. 06/04)
OMB Collection 0851-0027 (exp. 6/30/2005)

U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

RECORDATION FORM COVER SHEET TRADEMARKS ONLY

To the Director of the U. S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies)/Execution Date(s):

Lynx Therapeutics, Inc.

- Individual(s)
- General Partnership
- Corporation-State
- Other: _____
- Association
- Limited Partnership

Citizenship: DE

Execution Date(s): 12/28/04

Additional names of conveying parties attached? Yes No

2. Name and address of receiving party(ies):

Additional names, addresses, or citizenship attached? Yes No

Name: Silicon Valley Bank dba Silicon Valley East

Internal Address: _____

Street Address: 3003 Tasman Drive

City: Santa Clara

State: CA

Country: US Zip: 95054

- Association
- General Partnership
- Limited Partnership
- Corporation
- Other: Chartered Bank

Citizenship: _____
Citizenship: _____
Citizenship: _____
Citizenship: _____
Citizenship: CA

If assignee is not domiciled in the United States, a domestic representative designation is attached: Yes No
(Designations must be a separate document from assignment)

3. Nature of conveyance:

- Assignment
- Security Agreement
- Other: _____
- Merger
- Change of Name

4. Application number(s) or registration number(s) and

A. Trademark Application No.(s):

75/631946 76/162496

identification or description of the Trademark(s):

B. Trademark Registration No.(s):

2607815 2756427 2650334 2503036 2505260
2646805 2640604 2661846 2661848 2586627
2856295

Additional sheet(s) attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Christopher E. Kondracki

Address: 2001 Jefferson Davis Highway

Suite 1007

Arlington, Virginia 22202

Phone Number: (703) 415-1555

Fax Number: (703) 415-1557

Email Address: _____

6. Total number of applications and registrations involved:

13

7. Total Fee (37 CFR 2.6(b)(6) & 3.41):

\$ 340.00


- Authorized to be charged by credit card
- Authorized to be charged by Deposit Account
- Fees Enclosed

8. Payment Information:

Deposit Account Number: 19-3545

Authorized User Name: Christopher E. Kondracki

9. Signature:



Signature

January 4, 2005

Date

Christopher E. Kondracki
Name of Person Signing

Total number of pages including cover sheet, attachments, and documents: **32**

CH \$340.00 193645 75631946

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (this "IP Agreement") is made as of the 28th day of December, 2004 by and between LYNX THERAPEUTICS, INC., a Delaware corporation with its principal place of business at 25861 Industrial Boulevard, Hayward, California 94545 ("Grantor"), and SILICON VALLEY BANK, a California-chartered bank, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at One Newton Executive Park, Suite 200, 2221 Washington Street, Newton, Massachusetts 02462, doing business under the name "Silicon Valley East" ("Lender").

RECITALS

A. Lender has agreed to make advances of money and to extend certain financial accommodations to Grantor (the "Loan"), pursuant to a certain Loan and Security Agreement dated as of December 28, 2004 between Grantor and Lender, as amended from time to time (as amended, the "Loan Agreement"). The Loan is secured pursuant to the terms of the Loan Agreement. Lender is willing to enter into certain financial accommodations with Grantor, but only upon the condition, among others, that Grantor shall grant to Lender a security interest in certain Copyrights, Trademarks, Patents, and Mask Works, and other assets, to secure the obligations of Grantor under the Loan Agreement. Defined terms used but not defined herein shall have the same meanings as in the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Lender a security interest in all of Grantor's right title and interest, whether presently existing or hereafter acquired in, to and under all of the Collateral (as defined therein).

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged and intending to be legally bound, as collateral security for the prompt and complete payment when due of Grantor's Indebtedness (as defined below), Grantor hereby represents, warrants, covenants and agrees as follows:

1. Grant of Security Interest. As collateral security for the prompt and complete payment and performance of all of Grantor's present or future indebtedness, obligations and liabilities to Lender (hereinafter, the "Indebtedness"), including, without limitation, under the Loan Agreement, Grantor hereby grants a security interest in all of Grantor's right, title and interest in, to and under its registered and unregistered intellectual property collateral (all of which shall collectively be called the "Intellectual Property Collateral"), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished, registered or unregistered, and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on EXHIBIT A attached hereto (collectively, the "Copyrights");

(b) Any and all trade secret rights, including any rights to unpatented inventions, know-how, operating manuals, license rights and agreements, and confidential information, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights which may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on EXHIBIT B attached hereto (collectively, the "Patents");

(e) Any trademark and service mark rights, slogans, trade dress, and tradenames, trade styles, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on EXHIBIT C attached hereto (collectively, the "Trademarks");

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on EXHIBIT D attached hereto (collectively, the "Mask Works");

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights, including, without limitation those set forth on EXHIBIT E attached hereto (collectively, the "Licenses");

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

2. Authorization and Request. Grantor authorizes and requests that the Register of Copyrights and the Commissioner of Patents and Trademarks record this IP Agreement, and any amendments thereto, or copies hereof.

3. Covenants and Warranties. Grantor represents, warrants, covenants and agrees as follows:

(a) Except as set forth in the Perfection Certificate, Grantor is now the sole owner of the Intellectual Property Collateral, except for non-exclusive licenses granted by Grantor to its customers in the ordinary course of business;

(b) Performance of this IP Agreement does not conflict with or result in a breach of any material agreement to which Grantor is bound;

(c) During the term of this IP Agreement, Grantor will not transfer or otherwise encumber any interest in the Intellectual Property Collateral, except for non-exclusive licenses granted by Grantor in the ordinary course of business or as set forth in this IP Agreement;

(d) To its knowledge, each of the Patents is valid and enforceable, and no part of the Intellectual Property Collateral has been judged invalid or unenforceable, in whole or in part, and no claim has been made that any part of the Intellectual Property Collateral violates the rights of any third party;

(e) Grantor shall promptly advise Lender of any material adverse change in the composition of the Collateral, including but not limited to any subsequent ownership right of the Grantor in or to any Trademark, Patent, Copyright, or Mask Work specified in this IP Agreement;

(f) Grantor shall (i) protect, defend and maintain the validity and enforceability of the Trademarks, Patents, Copyrights, and Mask Works, (ii) use its best efforts to detect infringements of the Trademarks, Patents, Copyrights, and Mask Works and promptly advise Lender in writing of material infringements detected and (iii) not allow any Trademarks, Patents, Copyrights, or Mask Works to be abandoned, forfeited or dedicated to the public without the written consent of Lender, which shall not be

unreasonably withheld, unless Grantor determines that reasonable business practices suggest that abandonment is appropriate;

(g) Grantor shall take such further actions as Lender may reasonably request from time to time to perfect or continue the perfection of Lender's interest in the Intellectual Property Collateral;

(h) This IP Agreement creates, and in the case of after acquired Intellectual Property Collateral this IP Agreement will create, at the time Grantor first has rights in such after acquired Intellectual Property Collateral, in favor of Lender a valid and perfected first priority security interest and collateral assignment in the Intellectual Property Collateral in the United States securing the payment and performance of the obligations evidenced by the Loan Agreement;

(i) To its knowledge, except for, and upon, the filing of UCC financing statements, or other notice filings or notations in appropriate filing offices, if necessary to perfect the security interests created hereunder, no authorization, approval or other action by, and no notice to or filing with, any U.S. governmental authority or U.S. regulatory body is required either (a) for the grant by Grantor of the security interest granted hereby, or for the execution, delivery or performance of this IP Agreement by Grantor in the U.S. or (b) for the perfection in the United States or the exercise by Lender of its rights and remedies thereunder;

(j) All information heretofore, herein or hereafter supplied to Lender by or on behalf of Grantor with respect to the Intellectual Property Collateral is accurate and complete in all material respects;

(k) Grantor shall not enter into any agreement that would materially impair or conflict with Grantor's obligations hereunder without Lender's prior written consent, which consent shall not be unreasonably withheld. Grantor shall not permit the inclusion in any material contract to which it becomes a party of any provisions that could or might in any way prevent the creation of a security interest in Grantor's rights and interest in any property included within the definition of the Intellectual Property Collateral acquired under such contracts; and

(l) Upon any executive officer of Grantor obtaining actual knowledge thereof, Grantor will promptly notify Lender in writing of any event that materially adversely affects the value of any material Intellectual Property Collateral, the ability of Grantor to dispose of any material Intellectual Property Collateral or the rights and remedies of Lender in relation thereto, including the levy of any legal process against any of the Intellectual Property Collateral.

4. Lender's Rights. Lender shall have the right, but not the obligation, to take, at Grantor's sole expense, any actions that Grantor is required under this IP Agreement to take but which Grantor fails to take, after fifteen (15) days' notice to Grantor. Grantor shall reimburse and indemnify Lender for all reasonable costs and reasonable expenses incurred in the reasonable exercise of its rights under this section 4.

5. Inspection Rights. Grantor hereby grants to Lender and its employees, representatives and agents the right to visit, during reasonable hours upon prior reasonable written notice to Grantor, any of Grantor's plants and facilities that manufacture, install or store products (or that have done so during the prior six-month period) that are sold utilizing any of the Intellectual Property Collateral, and to inspect the products and quality control records relating thereto upon reasonable written notice to Grantor and as often as may be reasonably requested, but not more than once in every six (6) months; provided, however, nothing herein shall entitle Lender access to Grantor's trade secrets and other proprietary information.

6. Further Assurances; Attorney in Fact.

(a) On a continuing basis, Grantor will, upon request by Lender, subject to any prior licenses, encumbrances and restrictions and prospective licenses, make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate

financing and continuation statements and collateral agreements and filings with the United States Patent and Trademarks Office and the Register of Copyrights, and take all such action as may reasonably be deemed necessary or advisable, or as requested by Lender, to perfect Lender's security interest in all Copyrights, Patents, Trademarks, and Mask Works and otherwise to carry out the intent and purposes of this IP Agreement, or for assuring and confirming to Lender the grant or perfection of a security interest in all Intellectual Property Collateral.

(b) In addition to section 6(a) above, Grantor shall not register any Copyrights or Mask Works in the United States Copyright Office unless it: (i) has given at least fifteen (15) days' prior written notice to Lender of its intent to register such Copyrights or Mask Works and has provided Lender with a copy of the application it intends to file with the United States Copyright Office (excluding exhibits thereto); (ii) executes a security agreement or such other documents as Lender may reasonably request in order to maintain the perfection and priority of Lender's security interest in the Copyrights proposed to be registered with the United States Copyright Office; and (iii) records such security documents with the United States Copyright Office contemporaneously with filing the Copyright application(s) with the United States Copyright Office. Grantor shall promptly provide to Lender a copy of the Copyright application(s) filed with the United States Copyright Office, together with evidence of the recording of the security documents necessary for Lender to maintain the perfection and priority of its security interest in such Copyrights or Mask Works. Grantor shall provide written notice to Lender of any application filed by Grantor in the United States Patent Trademark Office for a patent or to register a trademark or service mark within 30 days of any such filing.

(c) Grantor hereby irrevocably appoints Lender as Grantor's attorney-in-fact, with full authority in the place and stead of Grantor and in the name of Grantor, Lender or otherwise, from time to time in Lender's discretion, upon Grantor's failure or inability to do so, to take any action and to execute any instrument which Lender may deem necessary or advisable to accomplish the purposes of this IP Agreement, including:

(i) To modify, in its sole discretion, this IP Agreement without first obtaining Grantor's approval of or signature to such modification by amending Exhibit A, Exhibit B, Exhibit C, and Exhibit D hereof, as appropriate, to include reference to any right, title or interest in any Copyrights, Patents, Trademarks or Mask Works acquired by Grantor after the execution hereof or to delete any reference to any right, title or interest in any Copyrights, Patents, Trademarks, or Mask Works in which Grantor no longer has or claims any right, title or interest; and

(ii) To file, in its sole discretion, one or more financing or continuation statements and amendments thereto, or other notice filings or notations in appropriate filing offices, relative to any of the Intellectual Property Collateral, without notice to Grantor, with all appropriate jurisdictions, as Lender deems appropriate, in order to further perfect or protect Lender's interest in the Intellectual Property Collateral.

7. Events of Default. The occurrence of any of the following shall constitute an Event of Default under this IP Agreement:

- (a) An Event of Default occurs under the Loan Agreement; or
- (b) Grantor breaches any warranty or agreement made by Grantor in this IP Agreement.

8. Remedies. Upon the occurrence and continuance of an Event of Default, Lender shall have the right to exercise all the remedies of a secured party under the California Uniform Commercial Code, including without limitation the right to require Grantor to assemble the Intellectual Property Collateral and any tangible property in which Lender has a security interest and to make it available to Lender at a place designated by Lender. Lender shall have a nonexclusive, royalty free license to use the Copyrights, Patents, Trademarks, and Mask Works to the extent reasonably necessary to permit Lender to exercise its rights and remedies upon the occurrence of an Event of Default. Grantor will pay any expenses (including reasonable attorney's fees) incurred by Lender in connection with the exercise of any of Lender's rights hereunder, including without limitation any expense incurred

in disposing of the Intellectual Property Collateral. All of Lender's rights and remedies with respect to the Intellectual Property Collateral shall be cumulative.

9. Indemnity. Grantor agrees to defend, indemnify and hold harmless Lender and its officers, employees, and agents against: (a) all obligations, demands, claims, and liabilities claimed or asserted by any other party in connection with the transactions contemplated by this IP Agreement, and (b) all losses or expenses in any way suffered, incurred, or paid by Lender as a result of or in any way arising out of, following or consequential to transactions between Lender and Grantor, whether under this IP Agreement or otherwise (including without limitation, reasonable attorneys fees and reasonable expenses), except for losses arising from or out of Lender's gross negligence or willful misconduct.

10. Termination. At such time as Grantor shall completely satisfy all of the obligations secured hereunder, Lender shall execute and deliver to Grantor all releases, terminations, and other instruments as may be necessary or proper to release the security interest hereunder.

11. Course of Dealing. No course of dealing, nor any failure to exercise, nor any delay in exercising any right, power or privilege hereunder shall operate as a waiver thereof.

12. Amendments. This IP Agreement may be amended only by a written instrument signed by both parties hereto.

13. Counterparts. This IP Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute the same instrument.

14. Law and Jurisdiction. This IP Agreement shall be governed by and construed in accordance with the laws of the State of California. GRANTOR ACCEPTS FOR ITSELF AND IN CONNECTION WITH ITS PROPERTIES, UNCONDITIONALLY, THE NON-EXCLUSIVE JURISDICTION OF ANY STATE OR FEDERAL COURT OF COMPETENT JURISDICTION IN THE STATE OF CALIFORNIA, AND GRANTOR ACCEPTS JURISDICTION OF THE COURTS AND VENUE IN SANTA CLARA COUNTY, CALIFORNIA, IN ANY ACTION, SUIT, OR PROCEEDING OF ANY KIND, AGAINST IT WHICH ARISES OUT OF OR BY REASON OF THIS AGREEMENT. NOTWITHSTANDING THE FOREGOING, THE LENDER SHALL HAVE THE RIGHT TO BRING ANY ACTION OR PROCEEDING AGAINST THE GRANTOR OR ITS PROPERTY IN THE COURTS OF ANY OTHER JURISDICTION WHICH THE LENDER DEEMS NECESSARY OR APPROPRIATE IN ORDER TO REALIZE ON THE COLLATERAL OR TO OTHERWISE ENFORCE THE LENDER'S RIGHTS AGAINST THE GRANTOR OR ITS PROPERTY.

GRANTOR AND LENDER EACH HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF ANY OF THE LOAN DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREIN, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW OR STATUTORY CLAIMS. EACH PARTY RECOGNIZES AND AGREES THAT THE FOREGOING WAIVER CONSTITUTES A MATERIAL INDUCEMENT FOR IT TO ENTER INTO THIS AGREEMENT. EACH PARTY REPRESENTS AND WARRANTS THAT IT HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL AND THAT IT KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.

15. Confidentiality. In handling any confidential information, Lender shall exercise the same degree of care that it exercises for its own proprietary information, but disclosure of information may be made: (i) to Lender's subsidiaries or affiliates in connection with their present or prospective business relations with Grantor; (ii) to prospective transferees or purchasers of any interest in the Loans; (iii) as required by law, regulation, subpoena, or other order, (iv) as required in connection with Lender's examination or audit; and (v) as Lender considers appropriate in exercising remedies under this Agreement. Confidential information does not include information that either: (a) is in the public domain or in Lender's possession when disclosed to Lender, or becomes part of the

lic domain after disclosure to Lender; or (b) is disclosed to Lender by a third party, if Lender reasonably does not know that the third party is prohibited from disclosing the information.

[Remainder of page intentionally left blank]

EXECUTED under the laws of the State of California on the day and year first written above.

Address of Grantor:

25861 Industrial Boulevard
Hayward, California 94545

GRANTOR:

LYNX THERAPEUTICS, INC.

By: Mary L. Schramke

Name: MARY L. SCHRAMKE

Title: ACTING CHIEF EXECUTIVE OFFICER

SILICON VALLEY BANK

By: _____

Name: _____

Title: _____

EXECUTED under the laws of the State of California on the day and year first written above.

Address of Grantor:

25861 Industrial Boulevard

Hayward, California 94545

GRANTOR:

LYNX THERAPEUTICS, INC.

By: _____

Name: _____

Title: _____

SILICON VALLEY BANK

By:  _____

Name: Michael J. Hammer

Title: SR Vice President Life Sciences

Exhibit "A" attached to that certain Intellectual Property Security Agreement dated December 28, 2004.

EXHIBIT "A"

COPYRIGHTS

SCHEDULE A - ISSUED COPYRIGHTS

<u>COPYRIGHT DESCRIPTION</u>	<u>REGISTRATION NUMBER</u>	<u>DATE OF ISSUANCE</u>
------------------------------	----------------------------	-------------------------

None.

SCHEDULE B - PENDING COPYRIGHT APPLICATIONS

<u>FIRST DATE COPYRIGHT DESCRIPTION</u>	<u>APPLICATION NUMBER</u>	<u>DATE OF FILING</u>	<u>DATE OF CREATION</u>	<u>OF PUBLIC DISTRIBUTION</u>
-----------------------------------------	---------------------------	-----------------------	-------------------------	-------------------------------

None.

SCHEDULE C - UNREGISTERED COPYRIGHTS (Where No Copyright Application is Pending)

<u>COPYRIGHT DESCRIPTION</u>	<u>DATE OF CREATION</u>	<u>FIRST DATE OF DISTRIBUTION</u>	<u>DATE AND RECORDATION NUMBER OF IP AGREEMENT WITH OWNER OR ORIGINAL GRANTOR IF AUTHOR OR OWNER OF COPYRIGHT IS DIFFERENT FROM GRANTOR</u>	<u>ORIGINAL AUTHOR OR OWNER OF COPYRIGHT IS DIFFERENT FROM GRANTOR</u>
------------------------------	-------------------------	-----------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------

None.

Exhibit "B" attached to that certain Intellectual Property Security Agreement dated December 28, 2004.

EXHIBIT "B"

PATENTS

<u>PATENT</u>					
<u>DESCRIPTION</u>	<u>DOCKET NO.</u>	<u>COUNTRY</u>	<u>SERIAL NO.</u>	<u>FILING DATE</u>	<u>STATUS</u>

See Attached.

HN-500643-v1-Lynn Patent List.XLS

Exhib. A-B Patents

Title/Brief Description	Pub. No.	Country	Serial No.	Filed	Status	App. Ref. No.	App. No.	Patent No.	Issued
Method for Detecting Foreign DNA in a Host Genome	1004	US	10/606,400	6/20/03	Pending	10/606,400			
Method and Compositions for Ordering Restriction Fragments	1002-02 2D	US	10/706,118	11/12/03	Pending	10/706,118			
Method of Nucleic Acid Amplification	1005-C	US	10/449,010	6/2/03	Pending	10/449,010			
Methods of Nucleic Acid Amplification and Sequencing	1006	US	09/806,531	10/10/01	Pending	09/806,531			
Isothermal Amplification of Nucleic Acids on a Solid Support	1007	US	10/433,965	11/3/03	Pending	10/433,965			
Methods for Detecting Genome-wide Sequence Variations Associated with a Phenotype	1008	US	10/378,688	3/4/03	Pending	10/378,688			
Stacked Microfluidic Device	1009	US	10/138,889	5/2/02	Pending	10/138,889			
Molecular Tagging System	802-02 JP DIV	JP	2003-350142		Filed	2003-350142			
Method of Nucleic Acid Amplification	1005	US	09/402,277	9/30/99	Pending	09/402,277			
Electrophoresis Apparatus and Method	818 WOAU	AU	40929/99	5/21/99	Granted	40929/99			
Method for Making Complementary Oligonucleotide Tag Sets	817 AU	AU	1603100	11/1/99	Granted	1603100			
Molecular Tagging System	802-02 AU-2D	AU	52663/99	10/4/99	Filed	52663/99			
Polymorphic DNA Fragments and Uses Thereof	826-02 AU	AU	32378/00	2/2/00	Filed	32378/00			
DNA Sequencing by Stepwise Ligation and Cleavage	801-05 WOAU	AU	23791/95	3/24/95	Granted	23791/95			
Solid Phase Synthesis of Oligonucleotide N ^{3'} -P ^{5'} Phosphoram	035-01 WOAU	AU	6178/96	6/14/96	Granted	6178/96			
Oligonucleotide N ^{3'} -P ^{5'} Phosphoramidates: Hybridization and	005-01 AU	AU	21900/95	3/20/95	Granted	21900/95			
Molecular Tagging System	802-02 WOAU	AU	42778/96	10/12/95	Granted	42778/96			
Oligonucleotide Tags for Sorting and Identification	802-05 WOAU	AU	61020/96	6/6/96	Granted	61020/96			
DNA Sequencing by Parallel Oligonucleotide Extensions	805 AU	AU	55490/96	4/16/96	Granted	55490/96			
Sequencing by Ligation of Encoded Adaptors	808-1 WOAU	AU	33740/97	6/2/97	Granted	33740/97			
System and Apparatus for Sequential Processing of Analyses	815 WOAU	AU	77155/98	5/22/98	Granted	77155/98			
Improvements in Adaptor-Based Sequence Analysis	814 WOAU	AU	71213/98	4/14/98	Granted	71213/98			
Method of mapping restriction sites in polynucleotides	816-01 WOAU	AU	81709/98	6/25/98	Granted	81709/98			

HN-500643-v1-Lynx Patent List.xls

Soft Phase Selection of Differentially Expressed Genes	822-02 AU	AU	21139/99	1/8/99	Granted	21139/99	1/8/99	754929	
DNA Sequencing by Parallel Oligonucleotide Extensions	805-01 AU DIV	AU	4871300	4/16/96	Granted	4871300	4/16/96	754991	3/20/03
DNA Sequencing by Stepwise Ligation and Cleavage	801-05 AS	AT	95916916	3/24/95	Granted	95916916	3/24/95	EP00703991	5/16/01
DNA Sequencing by Stepwise Ligation and Cleavage	801-05 BE	BELG	95916916	3/24/95	Granted	95916916	3/24/95	EP0703991	5/16/01
Electrophoresis Apparatus and Method	818 WOCA	CA	2232775	5/21/99	Filed	2232775	5/21/99		
Method of Mapping Restriction Sites in Polynucleotides	818-01 WOCA	CA	2295325	6/25/98	Filed	2295325	6/25/98		
Oligonucleotide N3->P5' Phosphoranimides: Hybridization and	805-01 CA	CA	2184375	3/20/95	Filed	2184375	3/20/95		
DNA Sequencing by Stepwise Ligation and Cleavage	801-05 CA	CA	2163662	3/24/95	Filed	2163662	3/24/95		
Oligonucleotide Tags for Sorting and Identification	802-05 CA	CA	2222581	6/6/96	Granted	2222581	6/6/96	2222581	5/11/04
DNA Sequencing by Parallel Oligonucleotide Extensions	805 CA	CA	2218017	4/16/96	Granted	2218017	4/16/96	2218017	12/2/03
Massively Parallel Signature Sequencing by Ligation of Encoded Adaptors	808-1 WOCA	CA	2256700	6/2/97	Filed	2256700	6/2/97		
Data Analysis and Display System for Ligation-Based DNA Sequ	833-01 CA	CA	2386738	2/15/01	Filed	2386738	2/15/01		
Improvements in Adaptor-Based Sequence Analysis	814 WOCA	CA	2286400	4/14/98	Filed	2286400	4/14/98		
Polymorphic DNA Fragments and Uses Thereof	826-02 CA	CA	2372131	2/18/00	Filed	2372131	2/18/00		
Oligonucleotide Tags for Sorting and Identification	802-05 CA DIV	CA	2332731	6/6/96	Filed	2332731	6/6/96		
Molecular Tagging System	802-02 CA	CA	2202167	10/12/95	Granted	2202167	10/12/95	2202167	12/16/03
Solid Phase Synthesis of Oligonucleotide N3->P5' Phosphoram	035-01 WOCA	CA	2245666	6/14/96	Filed	2245666	6/14/96		
Method for Making Complementary Oligonucleotide Tag Sets	817 WOCA	CA	2349836	11/1/99	Filed	2349836	11/1/99		
System and Apparatus for Sequential Processing of Analytes	815 WOCA	CA	2291180	5/22/98	Filed	2291180	5/22/98		
Solid Phase Selection of Differentially Expressed Genes	822 WOCA	CA	2317695	1/8/99	Filed	2317695	1/8/99		
Oligonucleotide Tags for Sorting and Identification	802-05 CN	CHIN	96196135.X	6/6/96	Granted	96196135.X	6/6/96	96196135.X	4/21/04

Massively Parallel Signature Sequencing by Ligation of Encoded Adaptors	808-1 WOEN	CHIN	97197101.3	6/2/97	Filed	97197101.3	6/2/97		
Solid Phase Selection of Differentially Expressed Genes	822 WOCCZ	CZ	PV2000-2545	1/8/99	Filed	PV2000-2545	1/8/99		
Molecular Tagging System	802-02 WOCCZ	CZ	PV 866-97	10/12/95	Inactive	PV 866-97	10/12/95		
Sequencing by Ligation of Encoded Adaptors	808-1 WOCCZ	CZ	PV-397898	6/2/97	Inactive	PV-397898	6/2/97		
Oligonucleotide Tags for Sorting and Identification	802-05 CZ	CZ	PV3926-97	6/6/96	Inactive	PV3926-97	6/6/96		
Solid Phase Synthesis of Oligonucleotide N3->P5' Phosphoramidates	035-01 WOCCZ	CZ	PV2629-98	6/14/96	Filed	PV2629-98	6/14/96		
Oligonucleotide N3->P5' Phosphoramidates: Hybridization and	005-01 CZ	CZ	PV2745-96	3/20/95	Filed	PV2745-96	3/20/95		
DNA Sequencing by Stepwise Ligation and Cleavage	801-05 DN	DENM	85816916	3/24/95	Granted	95916816	3/24/95	EP0703991	5/18/01
Electrophoresis Apparatus and Method	818 WOEP	EPC	98924423.9	5/21/99	Pending	98924423.9	5/21/99		
High Resolution Physical Maps of Genomic DNA	816-01 WOEP	EPC	98931639.3	6/25/98	Pending	98931639.3	6/25/98		
Synthesis of Branched Nucleic Acids	003 WOEP	EPC	94923335.7	7/5/94	Abandoned	94923335.7	7/5/94		
Oligonucleotide N3->P5' Phosphoramidates: Hybridization and	005-01 EP	EPC	95914800.8	3/20/95	Pending	95914800.8	3/20/95		
Solid Phase Synthesis of Oligonucleotide N3->P5' Phosphoramidates	035-01 WOEP	EPC	96919449.7	6/14/96	Granted	96919449.7	6/14/96		
Oligonucleotide Tags for Sorting and Identification	802-05 EP	EPC	96918333.4	6/6/96	Pending	96918333.4	6/6/96		
DNA Sequencing by Parallel Oligonucleotide Extensions	805 EP	EPC	96912800.8	4/16/96	Pending	96912800.8	4/16/96		
Measurement of Gene Expression Profiles in Toxicity Determination	813 EP	EPC	96940238.7	10/11/96	Abandoned	96940238.7	10/11/96		
Massively Parallel Sequencing of Sorted Polynucleotides	803-01 EP	EPC	99105019.6	3/19/99	Pending	99105019.6	3/19/99		
Data Analysis and Display System for Ligation-Based DNA Sequencing	833-01 EP	EPC	1910827.3	2/15/01	Pending	1910827.3	2/15/01		
Improvements in Adaptor-Based Sequence Analysis	814 WOEP	EPC	98918252.2	4/14/98	Pending	98918252.2	4/14/98		
Massively Parallel Signature Sequencing by Ligation of Encoded Adaptors	808-1 WOEP	EPC	97929757.9	6/2/97	Pending	97929757.9	6/2/97		
Polymorphic DNA Fragments and Uses Thereof	826-02	EPC	910255.9	2/2/00	Pending	910255.9	2/2/00		
Methods for Sorting Polynucleotides Using Oligonucleotide Tag	802-02 EP	EPC	95941325.3	10/12/95	Pending	95941325.3	10/12/95		

HN-500643-v1-Lynn Patent List.XLS

Oligonucleotide Clamps Having Diagnostic and Therapeutic App	004 EP	EPC	94921471.2	7/1/94	Abandoned	94921471.2	7/1/94		
Method for Making Complementary Oligonucleotide Tag Sets	817 WOEP	EPC	98958733	11/1/99	Pending	98958733	11/1/99		
System and Apparatus for Sequential Processing of Analytes	815 WOEP	EPC	98925137.6	5/22/98	Pending	98925137.6	5/22/98		
Solid Phase Selection of Differentially Expressed Genes	822 WOEP	EPC	99901448.3	1/8/99	Pending	99901448.3	1/8/99		
DNA Sequencing by Stepwise Ligation and Cleavage	801-05 EP	EPC	95916916	3/24/95	Granted	95916916	3/24/95	EP0703991	5/16/01
Massively Parallel Sequencing of Sorted Polynucleotides	803 EP	EPC	95937322.6	10/12/95	Granted	95937322.6	10/12/95	EP0786014	
Simultaneous Sequencing of Tagged Polynucleotides	807 EP	EPC	96942790.5	11/19/96	Granted	96942790.5	11/19/96	EP0940803	5/2/03
Oligonucleotide N3->PS Phosphoramidates: Hybridization and	005-01 FI	FINL	963581	3/20/95	Filed	963581	3/20/95		
Molecular Tagging System	802-02 WOFN	FINL	971473	10/12/95	Filed	971473	10/12/95		
DNA Sequencing by Stepwise Ligation and Cleavage	801-05 FR	FR	95916916	3/24/95	Granted	95916916	3/24/95	EP0703991	5/16/01
Massively Parallel Sequencing of Sorted Polynucleotides	803 FR	FR	95937322.6	10/12/95	Granted	95937322.6	10/12/95	EP0786014	12/15/99
DNA Sequencing by Stepwise Ligation and Cleavage	801-05 GB	GB	95916916	3/24/95	Granted	95916916	3/24/95	EP0703991	5/16/01
mRNA Molecules for Use as Indicators for the Activation and	501 DE	GERM	10021834.2	5/6/00	Filed	10021834.2	5/6/00		
Massively Parallel Sequencing of Sorted Polynucleotides	803 DE	DE	95937322.6	10/12/95	Granted	95937322.6	10/12/95	EP0786014	12/15/99
DNA Sequencing by Stepwise Ligation and Cleavage	801-05 DE	DE	69520917.5-0	3/24/95	Granted	69520917.5-08	3/24/95	EP0703991	5/16/01
System and Apparatus for Sequential Processing of Analytes	815 WOEPHK	HK	105481.5	9/1/00	Filed	105481.5	9/1/00		
Massively Parallel Signature Sequencing by Ligation of Encoded Adaptors	808-1 HK	HK	99105687.9	12/4/99	Filed	99105687.9	12/4/99		
Oligonucleotide Tags for Sorting and Identification	802-05 HK	HK	99100227.7	1/16/99	Filed	99100227.7	1/16/99		
Solid Phase Selection of Differentially Expressed Genes	822 WOHH	HU	P0100242	1/8/99	Inactive	P0100242	1/8/99		
Molecular Tagging System	802-02 HU	HU	P8801187	10/12/95	Filed	P8801187	10/12/95		
Sequencing by Ligation of Encoded Adaptors	809-1 WOHH	HU	P0003944	6/2/97	Filed	P0003944	6/2/97		

TRADEMARK

REEL: 003004 FRAME: 0733

Oligonucleotide Tags for Sorting and Identification	802-05 HU	HU	P9900910	6/6/96	Filed	P9900910	6/6/96		
Solid Phase Synthesis of Oligonucleotide N3'->P5' Phosphoramidite	035-01 WO/HU	HU	P9902526	6/14/96	Filed	P9902526	6/14/96		
Oligonucleotide N3'->P5' Phosphoramidates: Hybridization and	005-01 HU	HU	P9602549	3/20/95	Filed	P9602549	3/20/95		
DNA Sequencing by Stepwise Ligation and Cleavage	801-05 IR	IREL	95916916	3/24/95	Granted	95916916	3/24/95	EP0703991	5/16/01
DNA Sequencing by Stepwise Ligation and Cleavage	801-05 IT	ITAL	95916916	3/24/95	Granted	95916916	3/24/95	EP0703991	5/16/01
Electrophoresis Apparatus and Method	818 WO/JP	JP	2000-551249	5/21/99	Filed	2000-551249	5/21/99		5/16/01
High Resolution Physical Maps of Genomic DNA Synthesis of Branched Nucleic Acids	816-01 WO/JP	JP	11-505776	6/25/98	Filed	11-505776	6/25/98		
Solid Phase Synthesis of Oligonucleotide N3'->P5' Phosphoramidite	003 JP	JP	7-503693	7/5/94	Inactive	7-503693	7/5/94		
Molecular Tagging System	035-01 WO/JP	JP	9-530107	6/14/96	Filed	9-530107	6/14/96		
DNA Sequencing by Parallel Oligonucleotide Extensions	802-02 WO/JP	JP	8513298	10/12/95	Filed	8513298	10/12/95		
Sequencing by Ligation of Encoded Adaptors	805 JP	JP	8531848	4/16/96	Filed	8531848	4/16/96		
Measurement of Gene Expression Profiles in Toxicity Determin	808-1 WO/JP	JP	10-500755	6/2/97	Filed	10-500755	6/2/97		
Improvements in Adaptor-Based Sequence Analysis	813 WO/JP	JP	09/515,240	10/11/96	Filed	09/515,240	10/11/96		
DNA Extension and Analysis with Rolling Primers	814 WO/JP	JP	10544260	4/14/98	Filed	10544260	4/14/98		
Polymorphic DNA Fragments and Uses Thereof	811-01 JP	JP	10-237840	8/24/98	Filed	10-237840	8/24/98		
Oligonucleotide Tags for Sorting and Identification	826-02 JA	JP	2000-601195	2/2/00	Filed	2000-601195	2/2/00		
DNA Sequencing by Stepwise Ligation and Cleavage	802-05 JP	JP	9-501818	6/6/96	Filed	9-501818	6/6/96		
Oligonucleotide N3'->P5' Phosphoramidates: Hybridization and	801-05 JP	JP	7525765	3/24/95	Filed	7525765	3/24/95		
Method for Making Complementary Oligonucleotide Tag Sets	005-01 JP	JP	7-524793	3/20/95	Filed	7-524793	3/20/95		
System and Apparatus for Sequential Processing of Analytes	817 WO/JP	JP	2000-579783	11/1/99	Filed	2000-579783	11/1/99		
Solid Phase Selection of Differentially Expressed Genes	815 WO/JP	JP	10-550757	5/22/98	Filed	10-550757	5/22/98		
	822 WO/JP	JP	2000-527674	1/8/99	Filed	2000-527674	1/8/99		

Solid Phase Selection of Differentially Expressed Genes	822 WO/KR	KR	2000-7007584	1/8/99	Granted	2000-7007585	1/8/99	433782	5/16/04
Oligonucleotide Tags for Sorting and Identification	802-05 KR	KR	97-709024	6/6/96	Inactive	97-709024	6/6/96		
Molecular Tagging System	802-02 WO/KR	KR	97-702433	10/12/95	Inactive	97-702433	10/12/95		
Oligonucleotide N3->P5' Phosphoramidates:	005-01 KR	KR	96-705131	3/20/95	Filed	96-705131	3/20/95		
Hybridization and	801-05 LX	LUXE	95916916	3/24/95	Granted	95916916	3/24/95	EP0703991	5/16/01
DNA Sequencing by Stepwise Ligation and	801-05 NL	NETH	95916916	3/24/95	Granted	95916916	3/24/95	EP0703991	5/16/01
Cleavage	822 WO/NO	NO	20003531	1/8/99	Filed	20003531	1/8/99		
Solid Phase Selection of Differentially Expressed Genes	802-05 NO	NO	P975744	6/6/96	Filed	P975744	6/6/96		
Oligonucleotide Tags for Sorting and Identification	808-1 WO/NO	NO	P13985698	6/2/97	Filed	P13985698	6/2/97	733782	
Sequencing by Ligation of Encoded Adaptors	802-02 WO/NO	NO	P971644	10/12/95	Filed	P971644	10/12/95		
Molecular Tagging System	005-01 NO	NO	P963891	3/20/95	Filed	P963891	3/20/95		
Oligonucleotide N3->P5' Phosphoramidates:	826-02 WO	PCT	00/04349	2/2/00	Inactive	00/04349	2/2/00		
Hybridization and	818 WO	PCT	PCT/US99/11	5/21/99	Inactive	PCT/US99/1127	5/21/99		
Polymorphic DNA Fragments and Uses Thereof	822 WO	PCT	99/00666	1/8/99	Inactive	99/00666	1/8/99		
Electrophoresis Apparatus and Method	816-01 WO	PCT	98/13335	6/25/99	Inactive	98/13335	6/25/99		
Solid Phase Selection of Differentially Expressed Genes	003 WO	PCT	94/07557	7/5/94	Inactive	94/07557	7/5/94		
High Resolution Physical Maps of Genomic DNA	005-01 WO	PCT	95/03575	3/20/95	Inactive	95/03575	3/20/95		
Synthesis of Branches/Nucleic Acids	035-01 WO	PCT	96/10418	6/14/96	Inactive	96/10418	6/14/96		
Oligonucleotide N3->P5' Phosphoramidates:	801-05 WO	PCT	95/03678	3/24/95	Inactive	95/03678	3/24/95		
Hybridization and	802-05 WO	PCT	96/09513	6/6/96	Inactive	96/09513	6/6/96		
Solid Phase Synthesis of Oligonucleotide N3->P5' Phosphoramidates	805 WO	PCT	96/05245	4/16/96	Inactive	96/05245	4/16/96		
DNA Sequencing by Stepwise Ligation and	807 WO	PCT	96/18708	11/19/96	Inactive	96/18708	11/19/96		
Cleavage	828 WO	PCT	01/24271	8/3/01	Abandoned	01/24271	8/3/01		
Oligonucleotide Tags for Sorting and Identification									
DNA Sequencing by Parallel Oligonucleotide									
Extensions									
Simultaneous Sequencing of Tagged									
Polynucleotides									
Electrophoresis Apparatus and Method									

HN-500643-v1-Lynx Patent List.XLS

Measurement of Gene Expression Profiles in Toxicity Determin	813 WO	PCT	96/16342	10/11/96	Inactive	96/16342	10/11/96
Polymorphic DNA Fragments and Uses Thereof Sequencing By Proxy	826-03WO 843 WO	PCT PCT	04/26115 02/16792	8/21/01 5/29/02	Abandoned Abandoned	01/26115 02/16792	8/21/01 5/29/02
Genetic Analysis of Gene Expression in Helicobacter Method for the Analysis of Differential Gene Expression	903 WO 906 WO	PCT PCT	02/38591 02/36950	12/10/02	Abandoned	02/38591 02/36950	12/10/02 12/10/02
Identification of Genes Controlling Complex Traits Method for Determining Relative Abundance of Nucleic Acid Se	907 WO 832-01WO	PCT PCT	02/41381 01/30396	12/30/02	Abandoned	02/41381 01/30396	12/30/02 9/27/01
Improvements in Adaptor-Based Sequence Analysis	814 WO	PCT	98/07592	4/14/98	Inactive	98/07592	4/14/98
Enzymatic Synthesis of Oligonucleotide Tags	810-01 WO	PCT	99/22585	9/28/99	Inactive	99/22585	9/28/99
Massively Parallel Signature Sequencing by Ligation of Encoded Adaptors	808-1 WO	PCT	97/09472	6/2/97	Inactive	97/09472	6/2/97
Polynucleotide Detection by Isothermal Amplification	806 WO	PCT	98/15384	9/26/98	Abandoned	98/15384	9/26/96
Massively Parallel Sequencing of Sorted Polynucleotides	803 WO	PCT	95/12678	10/12/95	Inactive	95/12678	10/12/95
Molecular Tagging System	802-02 WO	PCT	95/12791	10/12/95	Inactive	95/12791	10/12/95
Polynucleotide Purification Method	038-01 WO	PCT	99/19273	9/14/98	Abandoned	99/19273	9/14/98
Auto-Ligating Oligonucleotide Antisense Compounds Having Dia	001-00 WO	PCT	PCT/US9407	7/11/94	Inactive	PCT/US940792	7/11/94
Oligonucleotide Clamps Having Diagnostic and Therapeutic App	004 WO	PCT	94/07541	7/1/94	Inactive	94/07541	7/1/94
Method for Making Complementary Oligonucleotide Tag Sets	817 WO	PCT	99/25680	11/1/99	Inactive	99/25680	11/1/99
System and Apparatus for Sequential Processing of Analytes	815 WO	PCT	98/11224	5/22/98	Inactive	98/11224	5/22/98
Method of Screening for Genetic Polymorphism	819 WO	PCT	99/20047	8/31/99	Abandoned	99/20047	8/31/99
Method and Compositions for Ordering Restriction Fragments	845-03 WO	PCT	PCT/US01/11	4/12/01	Inactive	PCT/US01/1198	4/12/01
Data Analysis and Display System for Ligation-Based DNA Sequ	833-01 WO	PCT	01/05032	2/15/01	Inactive	01/05032	2/15/01
Solid Phase Selection of Differentially Expressed Genes	822 WO/PL	PL	Unknown	1/8/99	Filed	Unknown	1/8/99
Sequencing by Ligation of Encoded Adaptors	808-1 WO/PL	PL	P331513	6/2/97	Inactive	P331513	6/2/97

Oligonucleotide Tags for Sorting and Identification	802-05 WQPL	PL	P324000	6/6/96	Inactive	P324000	6/6/96		
Solid Phase Synthesis of Oligonucleotide N3->P5' Phosphoramidite	036-01 WQPL	PL	P328639	6/14/96	Filed	P328639	6/14/96		
Oligonucleotide N3->P5' Phosphoramidates: Hybridization and	005-01 PL	PL	P316434	3/20/95	Filed	P316434	3/20/95		
DNA Sequencing by Stepwise Ligation and Cleavage	801-05 SG	SING	9501952-7	3/24/95	Granted	9501952-7	3/24/95	23650	5/18/98
Molecular Tagging System	802-02 SG	SG	9701328-8	10/12/95	Granted	9701328-8	10/12/95	39092	5/25/99
Oligonucleotide Tags for Sorting and Identification	802-05 SG	SG	9706203-6	6/6/96	Granted	9706203-8	6/6/96	53428	5/25/99
Sequencing by Ligation of Encoded Adaptors	808-1 WOSG	SG	9805810-0	6/2/97	Granted	9805810-0	6/2/97	60647	
Solid Phase Selection of Differentially Expressed Genes	822 WOSG	SG	200003472-8	1/8/99	Granted	200003472-8	1/8/99	74272	7/9/02
DNA Sequencing by Stepwise Ligation and Cleavage	801-05 SE	SWED	95916916	3/24/95	Inactive	95916916	3/24/95	EP0703991	5/18/01
Cleavage	801-05 CH	SWIT	95916916	3/24/95	Granted	95916916	3/24/95	EP0703991	5/18/01
Massively Parallel Signature Sequencing by Ligation of Encoded Adaptors	808-1 TW	TAIW	86107846	6/6/97	Inactive	86107846	6/6/97		
Method and Compositions for Ordering Restriction Fragments	1002-02	US	09/549,748	4/14/00	Granted	09/549,748	4/14/00	6720179	11/25/03
Polymorphic DNA Fragments and Uses Thereof	826P	US	60/121,023	2/22/99	Inactive	60/121,023	2/22/99		
Polymorphic DNA Fragments and Uses Thereof	826-01	US	60/158,483	10/8/99	Inactive	60/158,483	10/8/99		
Method and Compositions for Enhancing Signal-to-Noise Ratios	832P	US	60/235,940	9/27/00	Inactive	60/235,940	9/27/00		
Data Analysis and Display System for Ligation-Based DNA Sequencing	833-01	US	09/654,187	9/1/00	Pending	09/654,187	9/1/00		
Chemical Mismatch Detection	838	US			To be filed				
Detecting Genetically Engineered Modifications in Host Organ	844	US			To be filed				
Sequencing By Proxy	843	US	09/867,201	5/29/01	Pending	09/867,201	5/29/01		
Fluid Delivery Apparatus	839	US			To be filed				
Nucleic Acid Analysis by Sequence Transformations	820P	US	60/143,705	7/14/99	Inactive	60/143,705	7/14/99		
System and Apparatus for Sequential Processing of Analytes	815-01	US	09/908,130	7/17/01	Pending	09/908,130	7/17/01		

HN-500843-v1-Lynx Patent List.XLS

Genes	822-01	US	09/130,546	8/6/98	Granted	09/130,546	8/6/98	6265163	7/24/01
System and Apparatus for Sequential Processing of Analytes	815-03	US	09/907,795	7/17/01	Granted	09/907,795	7/17/01	6654505	11/23/03
Novel Oligonucleotides Having Modified Internucleoside Linka	9213	US	08/012,050	2/1/93	Inactive	08/012,050	2/1/93		
Novel Oligonucleotides Having Modified Internucleoside Linka	9213 FWC	US	09/948,507	10/10/97	Inactive	08/948,507	10/10/97		
Novel Oligonucleotides Having Modified Internucleoside Linka	9213 DIV A	US	08/465,961	6/6/95	Inactive	08/465,961	6/6/95		
Novel Oligonucleotides Having Modified Internucleoside Linka	9213 DIV D FWC	US	08/885,827	6/30/97	Inactive	08/885,827	6/30/97		
Novel Oligonucleotides Having Modified Internucleoside Linka	9213 DIV E	US	08/659,924	6/7/96	Inactive	08/659,924	6/7/96		
Convergent Synthesis of Branched Multiply Connected Macromol	003	US	08/087,386	7/2/93	Inactive	08/087,386	7/2/93		
Novel Oligonucleotides Having Modified Internucleoside Linka	9213 DIV D	US	08/500,524	7/1/95	Inactive	08/500,524	7/1/95		
Method for Making Complementary Oligonucleotide Tag Sets	817P	US	60/106,662	11/2/98	Inactive	60/106,662	11/2/98		
High Resolution Physical Maps of Genomic DNA Oligonucleotide N3'->P5' Phosphoramidates: Hybridization and	005-04	US	08/711,384	9/3/96	Inactive	08/711,384	9/3/96		
System and Apparatus for Sequential Processing of Analytes	815-02	US	09/908,131	7/17/01	Pending	09/908,131	7/17/01		
Oligodeoxyribonucleotide N3' P5' Phosphoramidates: Uses and	006-00	US	08/210,505	3/18/94	Inactive	08/210,505	3/18/94		
Auto-Ligating Oligonucleotide Antisense Compounds Having Dia	0012-01	US	08/478,721	6/6/95	Inactive	08/478,721	6/6/95		
Solid Phase Selection of Differentially Expressed Genes	822	US	09/005,222	1/9/98	Inactive	09/005,222	1/9/98		
Method of Screening for Genetic Polymorphism DNA Sequencing by Stepwise Ligation and Cleavage	801-01 (SLC1)	US	09/222,300	4/4/94	Inactive	09/222,300	4/4/94		
Improved Combinatorial Tag Structures	836	US			To be filed				
Method and Compositions for Arraying Microbeads on a Planar	835	US			To be filed				
Molecular Tagging System	802-01	US	08/322,348	10/13/94	Inactive	08/322,348	10/13/94		

Massively Parallel Signature Sequencing Methods Compositions for Sorting Polynucleotides	833P 802-04 RE	US	60/182,454 09/366,081	2/15/00 8/2/99	Inactive Pending	60/182,454 09/366,081	2/15/00 8/2/99		
Oligonucleotide Tags for Sorting and Identification Electrophoresis Apparatus and Method	802-06 828	US	09/052,816 09/636,212	3/31/98 8/10/00	Inactive Inactive	09/052,816 09/636,212	3/31/98 8/10/00		
Polymorphic DNA Fragments and Uses Thereof Formation of Solid-Phase Arrays of Polynucleotides by Chemic	826-03P 825	US	60/227,058 09/346,571	8/21/00 7/1/99	Inactive Inactive	60/227,058 09/346,571	8/21/00 7/1/99		
DNA Sequencing by Random Primer Extension Method for the Analysis of Differential Gene Expression	804 906P	US	08/091,603 60/341,030	7/13/93 12/11/01	Inactive Abandoned	08/091,603 60/341,030	7/13/93 12/11/01		
DNA Sequence Analysis By Stringency Class Primers	804-02	US	08/436,528	5/8/95	Abandoned	08/436,528	5/8/95		
DNA Sequencing by Random Primer Extension Genetic Analysis of Gene Expression	804-01 903P	US	08/436,084 00/341,031	5/8/95 12/11/01	Inactive Inactive	08/436,084 60/341,031	5/8/95 12/11/01		
Identification of Candidate Genes for the Atherosclerosis Su	901P	US	60/341,973	12/18/01	Abandoned	60/341,973	12/18/01		
Identification of Genes Controlling Complex Traits Massively Parallel Signature Sequencing by Ligation of Encoded Adaptors	907P 808-1	US	60/344,499 08/862,610	12/28/01 5/23/97	Abandoned Inactive	60/344,499 08/862,610	12/28/01 5/23/97		
Genes Affected by Cholesterol Treatment and During Adipogene	902P	US	60/347,286	1/9/02	Inactive	60/347,286	1/9/02		
Secreted and Cell Surface Polypeptides Affected by Cholester	905P	US	60/347,396	1/9/02	Inactive	60/347,396	1/9/02		
Enzymatic Synthesis of Oligonucleotide Tags	810P	US	60/103,030	10/5/98	Inactive	60/103,030	10/5/98		
Enzymatic Synthesis of Oligonucleotide Tags	810-02	US	09/756,830	1/8/01	Pending	09/756,830	1/8/01		
Polymorphic DNA Fragments and Uses Thereof Identification of Genes Associated With Growth in Plants	826-03 904P	US	09/034,020 60/347,288	8/21/01 1/9/02	Pending Inactive	09/034,020 60/347,288	8/21/01 1/9/02		
System and Apparatus for Sequential Processing of Analyses	815-04	US	09/907,787	7/17/01	Pending	09/907,787	7/17/01		
Palindrome Fix	827	US			Inactive				
Use of encoded bead populations	830	US			Inactive				
Decoder Pairs	834	US			Inactive				

Auto-Ligating Oligonucleotide Antisense Compounds	0012-00	US	08/089,999	7/9/93	Granted	08/089,999	7/9/93	5571903	11/5/96
Oligonucleotide N3'-fw/danw, P5' phosphoramidates; ligation DNA	005-02	US	08/478,470	6/6/95	Granted	08/478,470	6/6/95	5591607	1/7/97
DNA Sequencing by Stepwise Ligation and Cleavage	801-05 (SLC3)	US	08/410,116	3/24/95	Granted	08/410,116	3/24/95	5599675	2/4/97
Oligonucleotide N3'->P5' Phosphoramidates; Hybridization and nuclease resistance properties	005	US	214599	3/18/94	Granted	214599	3/18/94	5599922	2/4/97
Methods for Sorting Polynucleotides Using Oligonucleotide Tag	802-02	US	08/358,810	12/19/94	Granted	08/358,810	12/19/94	5604097	2/18/97
Oligonucleotide N3'->P5' Phosphoramidates; Hybridization and	005-03	US	08/473,015	6/6/95	Granted	08/473,015	6/6/95	5631135	5/20/97
Minimally cross-hybridizing sets of oligonucleotide tags	802-03	US	08/479,238	6/7/95	Granted	08/479,238	6/7/95	5635400	6/3/97
Oligonucleotides having modified internucleoside linkages	9213 DIV B	US	08/471,248	6/6/95	Granted	08/471,248	6/6/95	5646260	7/18/97
Process for making oligonucleotides having modified internuc	9213 DIV C	US	08/467,219	6/6/95	Granted	08/467,219	6/6/95	5648480	7/15/97
Compositions for Sorting Polynucleotides	802-04	US	08/484,712	6/7/95	Granted	08/484,712	6/7/95	5654413	9/5/97
Oligo-2 - Fluorionucleotide N3'->P5' Phosphoramidates	035-00	US	08/603,566	2/21/96	Granted	08/603,566	2/21/96	5684143	11/4/97
DNA Sequencing by Stepwise Ligation and Cleavage	801-06 (SLC4)	US	08/667,689	6/21/96	Granted	08/667,689	6/21/96	5714330	2/3/98
Oligodeoxyribonucleotide N3' P5' Phosphoramidates	006-01	US	08/465,368	6/5/95	Granted	08/465,368	6/5/95	5726297	3/10/98
Oligonucleotide Clamps	004-01	US	08/461,271	6/5/95	Granted	08/461,271	6/5/95	5741643	4/21/98
Polynucleotide Detection by Isothermal Amplification Using C	806	US	08/536,743	9/29/95	Granted	08/536,743	9/29/95	5747255	5/5/98
DNA Sequencing By Parallel Oligonucleotide Extensions	805	US	08/424,663	4/17/95	Granted	08/424,663	4/17/95	5750341	5/12/98
Simultaneous Sequencing of Tagged Polynucleotides	807	US	08/560,313	1/17/95	Granted	08/560,313	1/17/95	5763175	6/9/98
DNA Extension and Analysis with Rolling Primers	811	US	08/611,155	3/5/96	Granted	08/611,155	3/5/96	5780231	7/14/98
Oligonucleotide Clamps Having Diagnostic and Therapeutic Applications	004-02	US	08/713,685	6/17/96	Granted	08/713,685	6/17/96	5817795	10/6/98
Solid Phase Synthesis of Oligonucleotide N3'->P5' Phosphoram	035-01	US	08/663,918	6/14/96	Granted	08/663,918	6/14/96	5824793	10/20/98

TRADEMARK

REEL: 003004 FRAME: 0741

Convergent Synthesis of Branched Multiply Connected Macromolecular Structures Kits for DNA Sequencing by Stepwise Ligation and Cleavage	003-02	US	08/689,856	6/15/96	Granted	08/689,856	6/15/96	5830658	11/3/98
Oligonucleotide N3->P5' Phosphoramidates: Hybridization and nuclease resistance properties	801-04 (SLC3C2)	US	08/712,011	9/11/96	Granted	08/712,011	9/11/96	5831065	11/3/98
Oligonucleotide Tags for Sorting and Identification Method of Determining Zygosity by Ligation and Cleavage	802-05	US	08/477,306	6/6/95	Granted	08/477,306	6/6/95	5837835	11/7/98
Synthon for Synthesis of Oligonucleotide N3-P5 Phosphoramid	801-03 (SLC3C1)	US	08/478,239	7/6/95	Granted	08/478,239	7/6/95	5856093	1/5/99
Method of Sorting Polynucleotides	035-02	US	08/771,789	12/20/96	Granted	08/771,789	12/20/96	5859233	1/12/99
Massively Parallel Sequencing of Sorted Polynucleotides	803	US	08/485,105	6/7/95	Granted	08/485,105	6/7/95	5853722	1/28/99
Improvements in Adaptor-Based Sequence Analysis	803-01	US	08/359,295	12/19/94	Granted	08/359,295	12/19/94	5695934	12/9/97
Novel Oligonucleotides Having Modified Internucleoside Linka	814	US	08/842,608	4/15/97	Granted	08/842,608	4/15/97	5888737	4/30/99
DNA Extension and Analysis with Rolling Primers	9213 DIVE CPA	US	08/659,924	6/7/96	Granted	08/659,924	6/7/96	5932718	1/16/01
Oligonucleotide N3, 3'-phosphoramidates	811-01	US	08/916,120	8/22/97	Granted	08/916,120	8/22/97	5962228	10/5/99
DNA Sequencing by Parallel Oligonucleotide Extensions	005-05 US	US	08/700,448	1/10/97	Granted	08/700,448	1/10/97	5965720	10/7/99
Polynucleotide Purification Method	805-01	US	08/972,446	6/10/97	Granted	08/872,446	6/10/97	5989119	10/7/99
Electrophoresis Apparatus and Method	038-00	US	08/929,620	9/15/97	Granted	08/929,620	9/15/97	5998604	12/7/99
Massively Parallel Signature Sequencing by Ligation of Encoded Adaptors	818	US	09/084,041	5/22/98	Granted	08/084,041	5/22/98	6013165	1/1/00
Oligonucleotide Clamps Having Diagnostic and Therapeutic Applications	808-2	US	08/946,138	10/7/97	Granted	08/946,138	10/7/97	6013445	1/11/00
DNA Restriction Site Mapping	004-03	US	09/070,477	4/30/98	Granted	09/070,477	4/30/98	6048974	4/11/00
Gene Expression Analysis	845-01	US	09/028,128	2/23/98	Granted	08/028,128	2/23/98	6054276	4/25/00
Method, Apparatus and Computer Program Product for Determini	845-02	US	09/187,793	11/6/99	Granted	09/187,793	11/6/99	6136537	10/24/00
Compositions for Sorting Polynucleotides	802-11	US	09/089,853	6/3/98	Granted	09/089,853	6/3/98	6138077	10/24/00
Kits for Sorting and Identifying Polynucleotides	803-03	US	09/183,650	10/30/98	Granted	09/183,650	10/30/98	6140489	10/31/00
Oligonucleotide N3, 3'-phosphoramidate Duplexes	802-13	US	09/166,543	11/20/98	Granted	09/166,543	11/20/98	6150516	11/21/00
	005-06	US	09/923,386	8/3/97	Granted	08/923,386	9/3/97	6169170	11/2/01

Molecular Tagging System	802-02 CA DIV	CA	2,441,634	10/12/95	Filed	2,441,634	10/12/95		
Massively Parallel Sequencing of Sorted Polynucleotides	803 GB	GB	95937322.6	10/12/95	Filed	95937322.6	10/12/95		
Methods for Identifying Genes Regulating Desired Cell Phenotypes	819-01D	US	68263,807 10646,451	1/24/02 8/21/03	Pending Pending	68263,807 10646,451	1/24/02 8/21/03		
Method of Screening for Genetic Polymorphism	1004	PCT	PCT/US2003/	6/21/02	Pending	PCT/US2003/01	6/21/02		
Method for Detecting Foreign DNA in a Host Genome	802-10	US	09/131,009	8/7/98	Granted	09/131,009	8/7/98	6172214	1/9/01
Oligonucleotide Tags for Sorting and Identification	802-09	US	09/092,226	6/5/98	Granted	09/092,226	6/5/98	6172218	1/9/01
Oligonucleotide Tags for Sorting and Identification	814-01	US	09/225,652	1/5/99	Granted	09/225,652	1/5/99	6175002	1/16/01
Improvements in Adaptor-Based Sequence Analysis	818-01	US	09/448,908	11/23/99	Granted	09/448,908	11/23/99	6214191	4/10/01
Measurement of Gene Expression Profiles in Toxicity Determin	813	US	09/269,911	2/28/00	Granted	09/269,911	2/28/00	6228589	5/6/01
Oligonucleotide Tags for Sorting and Identification	802-12	US	09/130,862	6/6/98	Granted	09/130,862	6/6/98	6235475	5/22/01
Method of Detecting the Presence or Absence of a Plurality of Target Sequences Using Oligonucleotide Tags	802-08	US	09/090,809	6/4/98	Granted	09/090,809	6/4/98	6280935	8/28/01
DNA Sequencing by Parallel Oligonucleotide Extensions	805-02	US	09/280,270	3/29/99	Granted	09/280,270	3/29/99	6306,597	10/23/01
Oligonucleotide Tags for Sorting and Identification	802-07	US	09/053,116	4/1/98	Granted	09/053,116	4/1/98	6352828	3/5/02
Planar Arrays of Microparticle-Bound Polynucleotides	816 US	US	09/424,028	11/16/99	Granted	09/424,028	11/16/99	6406848	6/18/02
Solid Phase Selection of Differentially Expressed Genes	822-02	US	09/227,694	1/8/99	Granted	09/227,694	1/8/99	6511,802	1/29/03
Method of mapping restriction sites in polynucleotides	616-01 US	US	09/446,081	3/27/00	Granted	09/446,081	3/27/00	6518023	2/11/03
SYSTEM AND APPARATUS FOR SEQUENTIAL PROCESSING OF ANALYTES	815-01 AU	AU	83651/01	Inactive		83651/01			
METHOD OF MAPPING RESTRICTION SITES IN POLYNUCLEOTIDES	816-01 WOJP	JP	11505776	6/25/98	Pending	11505776	6/25/98		
DATA ANALYSIS AND DISPLAY SYSTEM FOR LIGATION-BASED DNA SEQUENCING		US	10/407,089	4/2/03	Pending	10/407,089	4/2/03		
LIGATION BASED DNA SEQUENCING	833-01 AU	AU	38391/01	2/15/01	Filed	38391/01	2/15/01		

TRADEMARK

REEL: 003004 FRAME: 0743

HN-500643-V1-Lynx Patent List.XLS

Constant Length Signatures for parallel sequencing of Polynucleotides	1001	US	10/424,281	4/25/03	Pending	10/424,281	4/25/03		
Constant Length Signatures for Parallel Sequencing of Polynucleotides	1001 W/O	PCT	US03/13076	4/25/03	Pending	US03/13076	4/25/03		
SOLID PHASE SELECTION OF DIFFERENTIALLY EXPRESSED GENES		PL	342114	1/8/99	Pending	342114	1/8/99		
METHOD FOR APPLYING A PH GRADIENT TO A MICROCHANNEL DEVICE	1000 W/O	PCT	02/40176	12/17/02	Inactive	02/40176	12/17/02		
Adaptor-based sequence analysis		US	225652	1/5/99	Granted	225652	1/5/99	6175002	1/16/01
Adaptor-based sequence analysis		US	842608	4/15/97	Granted	842608	4/15/97	5888737	3/30/99
Chromatographic separation of phosphorothioate oligonucleotides		US	50288	5/10/93	Granted	50288	5/10/93	5395928	3/7/95
Method of synthesizing sulfurylated oligonucleotide analogs		US	113725	8/27/93	Granted	113725	8/27/93	5292875	3/8/94

TRADEMARK

REEL: 003004 FRAME: 0744

Exhibit "C" attached to that certain Intellectual Property Security Agreement dated December 26, 2004.

EXHIBIT "C"

TRADEMARKS

<u>TRADEMARK</u> <u>DESCRIPTION</u>	<u>COUNTRY</u>	<u>SERIAL NO.</u>	<u>REG. NO.</u>	<u>STATUS</u>
----------------------------------------	----------------	-------------------	-----------------	---------------

See Attached.

Exhibit A - TRADEMARKS

Class	Source	Country	Trade Name	Goods or Nature of Mark	Serial No.	Registration No.
TM	CLOSED-To Dungeon	US	Megacclone	Reagents for scientific or research use; diagnostics reagents for clinical or medical laboratory use	75/631946	There is no Registration No. for this one as it was abandoned
TM	Registered	US	Megasort	Kits consisting primarily of probes for sorting particulate supports carrying immobilized biological molecules, such as nucleic acids, for scientific or research use	75/653709	2,607,815
TM	Registered	US	MPPSS	DNA sequence analyzer for parallel analysis of multiple nucleic acids attached to separate microparticles disposed in a planar array, and parts thereof	75/368237	2,756,427
SM	CLOSED-To Dungeon	US	Megatype	Providing DNA analysis services for others	76/162496	There is no Registration No. for this one as it was abandoned
SM	Registered	US	Lynx	Providing DNA analysis services for others	76/163491	2,650,334
TM	Registered	US	Combi-Bead	Microbead reagents used in scientific and clinical research procedures for separating, sorting, labeling, or analyzing polynucleotide analytes	75/910313	2,503,036
TM	Registered	US	Combi-Tag	Oligonucleotide reagents used in scientific research and clinical research procedures for separation, sorting, or labeling polynucleotide analytes	75/788982	2,505,260
TM	Registered	US	Megacclone	Reagents for scientific or research use	76/163492	2,646,805
SM	Registered	US	Megacclone	Providing DNA analysis services for others	76/163424	2,640,604
TM/S	Registered	Japan	Megasort	Kits for laboratory and/or clinical analysis, sorting, or segregation by flow sorting or flow cytometry particulate supports carrying immobilized biological molecules, such as nucleic acids; DNA analysis	11-76484	04/19/2002
TM/S	Registered	Europe Only	Megasort	Kits for carrying out analysis; Services for laboratory and/or clinical analysis; carrying out laboratory & clinical analysis by selection or segregation, flow separation or by flow	1 261 791	11/28/2001

500640 v1/HN
@q@_011.DOC

TRADEMARK

Class	Status	Country	Mark of Distinction	Goods or Services of Mark	Serial No.	Registration No.
TM	Registered	Japan	Megacitone	cytometry particulate supports carrying immobilized biological molecules	11-42716	10/20/2000
TM	Registered	Japan	MPPSS	Particulate supports with immobilized biological molecules for use in scientific research or clinical procedures, such as nucleic acid probe hybridization, gene expression analysis, DNA sequencing, drug discovery & kits that include such supports	10-28514	12/24/1999
TM	Registered	Japan	Combi-Tag	Equipment for nucleic acid analysis, other physical or chemical apparatus/instruments, measuring apparatus/instruments	2000-6598	07/27/2001
TM	Registered	Japan	Combi-Tag	Oligonucleotide for separating, sorting and/or labeling polynucleotide analytes [other than for medical and veterinary purposes]	2001-32345	06/01/2001
TM	Registered	Europe	Megacitone	Oligonucleotide for clinical & medical purposes for separating, sorting and/or labeling polynucleotide analytes	1 163 609	10/03/2000
TM	Registered	Europe	MPPSS	Particulate supports with immobilized biological molecules for use in scientific research or clinical procedures, such as nucleic acid probe hybridization, gene expression analysis, DNA sequencing, drug discovery, and kits that include such supports	779 363	09/08/1999
TM	Registered	Europe	Combi-Tag	Chemicals used in industry and science; chemical reagents for scientific and diagnostic use, reagents for use in medicine; equipment for nucleic acid analysis	1 520 428	04/09/2001
TM, SM	Registered	US	Lynx Genecatalog and design (box design)	Oligonucleotide used in scientific research and clinical procedures for separating, sorting, and/or labeling polynucleotide analytes	76/216817	2,661,846

TRADEMARK

TM/SM	Status	Country	Mark or File	Class of Service	Serial No.	Registering To
SM	Registered	US	Lynx Genecatalog and design (cat eyes design)	Scientific apparatus & instruments...; medical, hygienic & beauty care, veterinary & agricultural services, scientific & industrial research; computer programming, services of a medical bacteriological or chemical laboratory, technical advisory services.	76/216971	2,661,848
SM	CLOSED-To	Japan	Lynx	Analysis, cloning, sequencing, identification, characterization and research of genes	41355/2001	
SM	Registered	Japan	Megacclone	Providing DNA analysis services for others	41356/2001	07/05/2002
SM	Registered	Japan	Megatype	Providing DNA analysis services for others	41357/2001	07/05/2002
SM	Registered	Japan	MPPSS	Providing DNA analysis services for others	41358/2001	07/05/2002
TM/SM	Registered	Europe	Lynx	Reagents for scientific or research use; reagents for clinical or medical laboratory use; providing DNA analysis services for others	2 208 148	10/14/2002
SM	Registered	Europe	Megacclone	Providing DNA analysis services for others	2 208 767	05/17/2002
SM	Registered	Europe	Megatype	Providing DNA analysis services for others	2 207 421	06/12/2002
SM	Registered	Europe	MPPSS	Providing DNA analysis services for others	2 208 387	03/06/2002
SM	Registered	US	Megasort	Providing DNA analysis services for others	76/259442	2,586,627
SM	Pending	US	MPPSS	Providing DNA analysis services for others	76/259445	2,856,295
TM	Registered	Japan	Lynx	Reagents for analysis, cloning, sequencing, identification, and research of genes for scientific or industrial use	58162/2002	04/16/2004

TRADEMARK

Exhibit "D" attached to that certain Intellectual Property Security Agreement dated December 20, 2004.

EXHIBIT "D"

MASK WORKS

<u>MASK WORK</u> <u>DESCRIPTION</u>	<u>COUNTRY</u>	<u>SERIAL NO.</u>	<u>REG. NO.</u>	<u>STATUS</u>
----------------------------------------	----------------	-------------------	-----------------	---------------

None.

Exhibit "E" attached to that certain Intellectual Property Security Agreement dated December 20, 2004.

EXHIBIT "E"

LICENSES

1. Colony Technology Sharing Agreement, dated as of March 22, 2004, between Solexa Limited and the Company.
2. Deed, dated October 25, 2004, between Solexa Limited and the Company.
3. Master Development Agreement, dated October 28, 2004, by and between Solexa Limited and the Company.
4. Collaboration Agreement, dated October 1, 2000, by and between Takara Shuzo Co., Ltd. and the Company, as amended on December 19, 2002 and June 30, 2003.

(56120/938)

869803.1